– The aim of this study was to examine the efficacy of Prostaglandin E1 in treating erectile disturbances with different etiology. Two hundred patients aged between 20 and 87 years were treated for erectile dysfunction, which was organic in 70.5% cases, psychogenic in 22% and idiopathic in 7.5%. The PGE1 was administered in doses ranging from a minimum of 2.5 μg to a maximum of 60 μg (3 cases). The study also tried to discover some of the reasons which led many of the patients to interrupt the therapeutic self-injection programme.
IshiiN., WatanabeH., IrisawaC., KikucyY.: Therapeutic trial with prostaglandin E1 for organic impotence. In: Proceedings of the Fifth Conference on vasculogenic impotence and corpus cavernosum revascularization. Second World Meeting on Impotence. Prague, ISIR, 11:2, 1986.
2.
JunemanK.P., AikenP.: Pharmacotherapy of erectile dysfunction: a review. Int. J. Impotence Res., 1: 71–93, 1989.
3.
PomaraS.: SOS maschio. Edi Arbor, 107–112, 1996.
4.
HwangT.K., PomaraS., MelmanA.: Pulse volume plethysmography: important factors of wave form in arteriogenic impotence. Int. J. Impotence Res., Suppl.1: 87–93, 1990.
5.
KediaK.R.: Penilplethysmography useful in diagnosis of vasculogenic impotence. Urology, 22: 235, 1983.
6.
De WolfV.G.Non invasive vascular evaluation. In: Disorders of male sexual function. In: MontagueD.K. (Ed.). Chicago, Year book medical pubblisher, Inc., 4: 44–59, 1988.
7.
PomaraS., HwangT.K., MelmanA.: Perdita di sensibilità esterocettiva peniena in rapporto all'età, al diabete e alla sua durata, in pazienti con disturbi erettili. Aula Medica, IV (3): 329–339, 1991.
